Poliklinik gGmbH Chemnitz
- Address
- lock Available on a paid plan
Poliklinik gGmbH Chemnitz - Multiple Myeloma Research Center
Poliklinik gGmbH Chemnitz is a specialized clinical research facility with demonstrated expertise in multiple myeloma therapeutic development. The center participates in cutting-edge investigations of novel treatment modalities, including advanced bispecific antibody therapies and next-generation immunotherapies for hematologic malignancies.
- Relapsed and refractory multiple myeloma treatment optimization
- Pharmacokinetic studies of innovative bispecific T-cell engaging therapies
- Post-transplant maintenance therapy strategies in newly diagnosed multiple myeloma
The center's research portfolio encompasses both early-phase pharmacokinetic comparability studies and pivotal Phase 3 efficacy trials. Their work with elranatamab and teclistamab reflects a commitment to advancing personalized medicine approaches in multiple myeloma, spanning the entire disease continuum from newly diagnosed patients through relapsed and refractory disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Poliklinik gGmbH Chemnitz
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Pharmacokinetic Comparability Study of Pre- and Post-change Teclistamab in Relapsed/Refractory Multiple Myeloma Patients | Janssen Cilag International | Phase I | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Elranatamab | 1 | Unknown | 2022-04-28 | 2022-04-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.